The influence of direct and antithrombin-dependent thrombin inhibitors on the procoagulant and anticoagulant effects of thrombin

Thrombosis Research

Volumn 110, Issue 4, 2003, Pages 221-226

  Linder, Rikard ^a   Frebelius, Siw ^b   Grip, Lars ^c   Swedenborg, Jesper ^b  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Activated protein C; Endothelial cell; Fibrinopeptide A; Hirudin thrombin inhibitor; Melagatran

Indexed keywords

ACTIVATED PROTEIN C; ANTICOAGULANT AGENT; ANTITHROMBIN; DALTEPARIN; FIBRINOGEN; FIBRINOPEPTIDE A; HEPARIN; HIRUDIN; HIRUGEN; INOGATRAN; LOW MOLECULAR WEIGHT HEPARIN; MELAGATRAN; THROMBIN; THROMBIN INHIBITOR; THROMBOMODULIN;

ANTICOAGULATION; ARTICLE; BLOOD CLOTTING; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; ENDOTHELIUM CELL; FIBRIN POLYMERIZATION; HUMAN; HUMAN CELL; IC 50; INCUBATION TIME; PRIORITY JOURNAL; SAPHENOUS VEIN;

EID: 0242380341     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0049-3848(03)00344-X     Document Type: Article

References (29)

1. Neri Serneri G.F., Modesti A., Gensini F., Branzi A., Melandri G., Poggesi L.et al. Randomized comparison of subcutaneous heparin, intravenous heparin, and aspirin in unstable angina. Lancet. 345:1995;1201-1204.
2. Théroux P., Waters D., Qui S., McCans J., de Guise P., Juneau M. Aspirin versus heparin to prevent myocardial infarction during the acute phase of unstable angina. Circulation. 88:1993;2045-2048.
3. FRISC Low-molecular-weight heparin during instability in coronary artery disease, Fragmin during Instability in Coronary Artery Disease (FRISC) study group. Lancet. 347(9001):1996;561-568.
4. Cohen M., Demers C., Gurfinkel E.P., Turpie A.G., Fromell G.J., Goodman S.et al. Low-molecular-weight heparins in non-ST-segment elevation ischemia: the ESSENCE trial. Efficacy and safety of subcutaneous enoxaparin versus intravenous unfractionated heparin, in non-Q-wave coronary events. Am. J. Cardiol. 82(5B):1998;19L-24L.
5. Finkle C.D., St. Pierre A., Leblond L., Deschenes I., DiMaio J., Winocour P.D. BCH-2763, a novel potent parenteral thrombin inhibitor, is an effective antithrombotic agent in rodent models of arterial and venous thrombosis - comparisons with heparin, r-hirudin, hirulog, inogatran and argatroban. Thromb. Haemost. 79(2):1998;431-438.
6. Gast A., Tschopp T.B., Schmid G., Hilpert K., Ackermann J. Inhibition of clot-bound and free (fluid-phase thrombin) by a novel synthetic thrombin inhibitor (Ro 46-6240), recombinant hirudin and heparin in human plasma. Blood Coagul. Fibrinolysis. 5(6):1994;879-887.
7. Weitz J., Hudoda M., Masel D., Maraganore J., Hirsch J. Clot bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III independent inhibitors. J. Clin. Invest. 86:1990;385-391.
8. OASIS-2 Effects of recombinant hirudin (lepirudin) compared with heparin on death, myocardial infarction, refractory angina, and revascularisation procedures in patients with acute myocardial ischaemia without ST elevation: a randomised trial. Organisation to Assess Strategies for Ischemic Syndromes (OASIS-2) investigators. Lancet. 353(9151):1999;429-438.
9. The GUSTO IIb investigators A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes. N. Engl. J. Med. 335:1996;775-782.
10. The Thrombin Inhibition In Myocardial Ischemia (TRIM) Study Group A low molecular weight, selective thrombin inhibitor, inogatran, vs. heparin, for unstable coronary artery disease in 1209 patients. Eur. Heart J. 18:1997;1416-1425.
11. Klootwijk P., Lenderink T., Meij S., Boersma H., Melkert R., Umans V.A. et al. Anticoagulant properties, clinical efficacy and safety of efegatran, a direct thrombin inhibitor, in patients with unstable angina. Eur. Heart J. 20(15):1999;1101-1111.
12. Linder R., Blomback M., Egberg N., Grip L. Thrombin inhibitors suppress the thrombin-thrombomodulin-mediated generation of activated protein C. Thromb. Res. 95(2):1999;117-125.
13. Mattsson C., Menschik-Lundin A., Nylander S., Gyzander E., Deinum J. Effect of different types of thrombin inhibitors on thrombin/thrombomodulin modulated activation of protein C in vitro. Thromb. Res. 104(6):2001;475-486.
14. Linder R., Frebelius S., Jansson K., Swedenborg J. Inhibition of endothelial cell mediated generation of activated protein C by direct and antithrombin dependent thrombin inhibitors. Blood Coagul. Fibrinolysis. 14:2003;139-146.
15. Haegerstrand A., Gillis C., Bengtsson L. Serial cultivation of adult human endothelium from the great saphenous vein. J. Vasc. Surg. 16:1992;280-285.
16. Bourin M.C., Boffa M.C., Bjork I., Lindahl U. Functional domains of rabbit thrombomodulin. Proc. Natl. Acad. Sci. U. S. A. 83(16):1986;5924-5928.
17. Soria J., Soria C., Ryckewaert J.J. A solid phase immuno enzymological assay for the measurement of human fibrinopeptide A. Thromb. Res. 20(4):1980;425-435.
18. Kelly A.B., Maraganore J.M., Bourdon P., Hanson S.R., Harker L.A. Antithrombotic effects of synthetic peptides targeting various functional domains of thrombin. Proc. Natl. Acad. Sci. U. S. A. 89(13):1992;6040-6044.
19. Ye J., Liu L.W., Esmon C.T., Johnson A.E. The fifth and sixth growth factor-like domains of thrombomodulin bind to the anion-binding exosite of thrombin and alter its specificity. J. Biol. Chem. 267(16):1992;11023-11028.
20. Linder R., Frebelius S., Jansson K., Swedenborg J. Inhibition of endothelial cell-mediated generation of activated protein C by direct and antithrombin-dependent thrombin inhibitors. Blood Coagul. Fibrinolysis. 14(2):2003;139-146.
21. van der Bom J.G., Bots M.L., Haverkate F., Slagboom P.E., Meijer P., de Jong P.T.et al. Reduced response to activated protein C is associated with increased risk for cerebrovascular disease. Ann. Intern. Med. 125(4):1996;265-269.
22. Griffin J.H., Evatt B., Zimmerman T.S. Deficency of protein C in congenital thrombotic disease. J. Clin. Invest. 68:1981;1370-1373.
23. Dacosta A., Tardy-Poncet B., Isaaz K., Cerisier A., Mismetti P., Simitsidis S.et al. Prevalence of factor V Leiden (APCR) and other inherited thrombophilias in young patients with myocardial infarction and normal coronary arteries. Heart. 80(4):1998;338-340.
24. Demarmels B.F., Merlo C., Furlan M., Sulzer I., Binder B.R., Lammle B. No association of APC resistance with myocardial infarction. Blood Coagul. Fibrinolysis. 6(5):1995;456-459.
25. Holm J., Hillarp A., Zoller B., Erhardt L., Berntorp E., Dahlback B. Factor V Q506 (resistance to activated protein C) and prognosis after acute coronary syndrome. Thromb. Haemost. 81(6):1999;857-860.
26. Mansourati J., Da Costa A., Munier S., Mercier B., Tardy B., Ferec C.et al. Prevalence of factor V Leiden in patients with myocardial infarction and normal coronary angiography. Thromb. Haemost. 83(6):2000;822-825.
27. Rosendaal F.R., Siscovick D.S., Schwartz S.M., Beverly R.K., Psaty B.M., Longstreth W.T. Jr.et al. Factor V Leiden (resistance to activated protein C) increases the risk of myocardial infarction in young women. Blood. 89(8):1997;2817-2821.
28. Li Y.H., Chen J.H., Wu H.L., Shi G.Y., Huang H.C., Chao T.H.et al. G-33A mutation in the promoter region of thrombomodulin gene and its association with coronary artery disease and plasma soluble thrombomodulin levels. Am. J. Cardiol. 85(1):2000;8-12.
29. Wu K.K., Aleksic N., Ahn C., Boerwinkle E., Folsom A.R., Juneja H. Thrombomodulin Ala455Val polymorphism and risk of coronary heart disease. Circulation. 103(10):2001;1386-1389.